Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 10/20 | 0.47 |
| ▸ | GIPR | P48546 | 2/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | GLP1R | P43220 | 2/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.45 |
| ▸ | ESRRG | P62508 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ADCY6 | O43306 | 3/20 | 0.44 |
| ▸ | ADCY3 | O60266 | 3/20 | 0.44 |
| ▸ | ADCY9 | O60503 | 3/20 | 0.44 |
| ▸ | ADCY5 | O95622 | 3/20 | 0.44 |
| ▸ | ADCY8 | P40145 | 3/20 | 0.44 |
| ▸ | ADCY7 | P51828 | 3/20 | 0.44 |
| ▸ | ADCY2 | Q08462 | 3/20 | 0.44 |
| ▸ | ADCY1 | Q08828 | 3/20 | 0.44 |
| ▸ | ADCY4 | Q8NFM4 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3538160 | 1.00 | GCGR (0.47) | GCGRGIPRTMEM97SIGMAR1GLP1R | |
| SCHEMBL4085803 | 0.85 | GCGR (0.52) | GCGRTMEM97SIGMAR1GLP1REPHX2 | |
| SCHEMBL4085804 | 0.85 | GCGR (0.52) | GCGRTMEM97SIGMAR1GLP1REPHX2 | |
| SCHEMBL4094093 | 0.82 | GCGR (0.42) | GCGRTMEM97SIGMAR1GLP1ROPRK1 | |
| SCHEMBL2662959 | 0.82 | GCGR (0.42) | GCGRTMEM97SIGMAR1GLP1ROPRK1 | |
| SCHEMBL2662978 | 0.77 | GCGR (0.65) | GCGRGIPRGLP1RNR1H4EPHX2 | |
| SCHEMBL15942950 | 0.75 | RAB9A (0.65) | GCGRNR1H4EPHX2ESRRGNPC1 | |
| SCHEMBL2662590 | 0.74 | GCGR (0.62) | GCGRGIPRTMEM97SIGMAR1GLP1R | |
| SCHEMBL2663340 | 0.70 | NR1H4 (0.39) | NR1H4NPC1RAB9AMEN1CYP1A2 | |
| SCHEMBL10631142 | 0.70 | SMN1; SMN2 (0.71) | GCGRNR1H4EPHX2ESRRGNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807701-B2 | Dibenzylamine compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2010-10-05 | — | — | US | disclosed |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| US-20080146620-A1 | Dibenzylamine Compounds and Pharmaceutical Use Thereof | JAPAN TOBACCO INC. (JP) | 2008-06-19 | — | — | US | disclosed |
| US-7332514-B2 | Dibenzylamine compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2008-02-19 | — | — | US | disclosed |
| EP-1829858-A2 | Dibenzylamine compounds and pharmaceutical use thereof | Japan Tobacco, Inc. (JP) | 2007-09-05 | — | — | EP | disclosed |
| EP-1533292-B1 | DIBENZYLAMINE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2007-02-14 | — | — | EP | disclosed |
| EP-1183229-B1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK AS (DK) | 2005-10-26 | — | — | EP | disclosed |
| EP-1533292-A1 | DIBENZYLAMINE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-05-25 | — | — | EP | disclosed |
| US-6875760-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2005-04-05 | — | — | US | disclosed |
| US-20050059810-A1 | Dibenzylamine compound and medicinal use thereof | JAPAN TOBACCO INC | 2005-03-17 | — | — | US | disclosed |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2003-11-27 | — | — | US | disclosed |
| US-6503949-B1 | Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity | NORO NORDISK A/S (DK) | 2003-01-07 | — | — | US | disclosed |
| WO-2000069810-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059810-A1 | Dibenzylamine compound and medicinal use thereof | CETP, CES1, APOB | GCGR 2306/4885GIPR 2793/4885TMEM97 2417/4885 |
| US-20080146620-A1 | Dibenzylamine Compounds and Pharmaceutical Use Thereof | CETP, PCSK9, CES1 | GCGR 2144/4885GIPR 2331/4885TMEM97 2113/4885 |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | GLP1R, GPR119, GCGR | GCGR 3/4885GIPR 4/4885TMEM97 2238/4885 |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | GCGR 3/4885GIPR 4/4885TMEM97 2238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.